Larvol Delta - An-immune-exhaustion-signature-predicts-prognosis-and-identifies-patients-with-diffuse-large-Bcell-lymphoma-DLBCL-who-derive-preferential-benefit-from-chimeric-antigen-receptor-CART-cell-therapy

Columvi (glofitamab-gxbm) - Roche

http://www.ncbi.nlm.nih.gov/pubmed/42724625

Bo Zheng; Rong Li; Wanqian Hu; Ying Fang

Sep 12, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next